AP PHarma as announced that it has received a Complete Response Letter (CRL) from the FDA regarding its New Drug...
The AQUARIUS study shows that Tekturna/Rasilez (aliskiren), from Novartis, neither improves nor slows the progression of coronary atherosclerosis when given...
The ELIXA Phase IIIb study designed to assess the cardiovascular (CV) safety of Lyxumia (lixisenatide), from Sanofi, in adults with...
The treatment of insulin dependent diabetes mellitus. May be used for diabetics who require an insulin of prompt onset and short duration. It is a suitable preparation for admixture with longer acting insulins. It is particularly useful where intermittent, short term or emergency therapy is required, during initial stabilisation and in the treatment of labile diabetes.
scPharmaceuticals Inc. announced that it has resubmitted its 505(b)(2) New Drug Application (NDA) to the FDA seeking approval of Furoscix (subcutaneous furosemide) for the treatment of congestion in patients with heart failure.
scPharmaceuticals Inc. announced that the FDA has accepted for review the company’s New Drug Application (NDA) resubmission for Furoscix.
In Sanofi’s Q2 2015 earnings release it was confirmed that in late July 2015, a New Drug Application (NDA) for...
Alcon, the eye care division of Novartis, will hold its first Capital Markets Day for investors and analysts in relation...
Levosimendan is a calcium sensitizer and adenosine triphosphate-dependent potassium channel opener, which exerts sustained hemodynamic, symptomatic, and organ-protective effects.